InflaRxIFRX
IFRX
About: InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Employees: 74
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
8,280% more call options, than puts
Call options by funds: $419K | Put options by funds: $5K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
63% more capital invested
Capital invested by funds: $19.7M [Q3] → $32.1M (+$12.4M) [Q4]
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
7% more funds holding
Funds holding: 27 [Q3] → 29 (+2) [Q4]
0.21% more ownership
Funds ownership: 21.85% [Q3] → 22.07% (+0.21%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
371%
upside
Avg. target
$9.33
449%
upside
High target
$10
488%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Steven Seedhouse 7% 1-year accuracy 1 / 14 met price target | 488%upside $10 | Overweight Initiated | 29 Apr 2025 |
Guggenheim Yatin Suneja 24% 1-year accuracy 8 / 33 met price target | 488%upside $10 | Buy Maintained | 26 Mar 2025 |
HC Wainwright & Co. Edward White 22% 1-year accuracy 32 / 148 met price target | 371%upside $8 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
10 hours ago
InflaRx to Report First Quarter 2025 Results on May 7, 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.
Negative
Zacks Investment Research
1 month ago
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
1 month ago
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025.
Neutral
GlobeNewsWire
1 month ago
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses.
Neutral
GlobeNewsWire
2 months ago
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL.
Neutral
GlobeNewsWire
2 months ago
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned.
Neutral
GlobeNewsWire
2 months ago
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares.
Neutral
GlobeNewsWire
2 months ago
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten public offering of 8,250,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares. The purchase price of each pre-funded warrant is equal to the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which is the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are being sold by the Company. The offering is expected to close on February 18, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company's ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are to be sold by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
3 months ago
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY.
Charts implemented using Lightweight Charts™